E Buchdunger

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
    E Buchdunger
    Novartis Pharma AG, Oncology Research, CH 4002 Basel, Switzerland
    J Pharmacol Exp Ther 295:139-45. 2000
  2. ncbi New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
    G Bold
    Oncology Research, and Process Research, Novartis Pharma AG, CH 4002 Basel, Switzerland
    J Med Chem 43:2310-23. 2000
  3. ncbi Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src
    M Missbach
    Novartis Pharma AG, Therapeutic Areas Arthritis and Bone Metabolism, Basel, Switzerland
    Bioorg Med Chem Lett 10:945-9. 2000
  4. ncbi Tyrosine kinase inhibitors: from rational design to clinical trials
    P Traxler
    Novartis Pharma AG, Oncology Research, CH 4002 Basel, Switzerland
    Med Res Rev 21:499-512. 2001
  5. ncbi Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma
    T O'Reilly
    Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Cancer Chemother Pharmacol 55:307-17. 2005
  6. ncbi Imatinib: a selective tyrosine kinase inhibitor
    P W Manley
    Novartis Pharma Ltd, Basel, Switzerland
    Eur J Cancer 38:S19-27. 2002
  7. ncbi Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma
    C C Solorzano
    Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 7:2563-72. 2001
  8. ncbi Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis
    T Sjoblom
    Ludwig Institute for Cancer Research, S 751 24 Uppsala, Sweden
    Cancer Res 61:5778-83. 2001
  9. ncbi Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
    K Pietras
    Ludwig Institute for Cancer Research, Uppsala, Sweden
    Cancer Res 61:2929-34. 2001
  10. ncbi The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB
    A Shimizu
    Ludwig Institute for Cancer Research, Uppsala, Sweden
    Cancer Res 59:3719-23. 1999

Collaborators

Detail Information

Publications11

  1. ncbi Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
    E Buchdunger
    Novartis Pharma AG, Oncology Research, CH 4002 Basel, Switzerland
    J Pharmacol Exp Ther 295:139-45. 2000
    ....
  2. ncbi New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
    G Bold
    Oncology Research, and Process Research, Novartis Pharma AG, CH 4002 Basel, Switzerland
    J Med Chem 43:2310-23. 2000
    ..Since these 1-anilino-(4-pyridylmethyl)phthalazines are orally well absorbed, these compounds qualify for further profiling and as candidates for clinical evaluation...
  3. ncbi Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src
    M Missbach
    Novartis Pharma AG, Therapeutic Areas Arthritis and Bone Metabolism, Basel, Switzerland
    Bioorg Med Chem Lett 10:945-9. 2000
    ..The substitution pattern on the two phenyl rings determines potency and specificity and provides a means to modulate cellular activity...
  4. ncbi Tyrosine kinase inhibitors: from rational design to clinical trials
    P Traxler
    Novartis Pharma AG, Oncology Research, CH 4002 Basel, Switzerland
    Med Res Rev 21:499-512. 2001
    ..In addition, potent inhibition of the PDGFR and c-Kit tyrosine kinases also indicates its possible clinical use in solid tumors...
  5. ncbi Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma
    T O'Reilly
    Oncology Research, Novartis Institutes for BioMedical Research, Basel, Switzerland
    Cancer Chemother Pharmacol 55:307-17. 2005
    ....
  6. ncbi Imatinib: a selective tyrosine kinase inhibitor
    P W Manley
    Novartis Pharma Ltd, Basel, Switzerland
    Eur J Cancer 38:S19-27. 2002
    ..In this paper, the relationship between molecular biology and drug discovery methods, as utilized for the identification of anticancer drugs, will be illustrated...
  7. ncbi Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma
    C C Solorzano
    Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 7:2563-72. 2001
    ..Collectively, our results demonstrate that three weekly oral administrations of an EGFR tyrosine kinase inhibitor in combination with gemcitabine are sufficient to significantly inhibit primary and metastatic human pancreatic carcinoma...
  8. ncbi Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis
    T Sjoblom
    Ludwig Institute for Cancer Research, S 751 24 Uppsala, Sweden
    Cancer Res 61:5778-83. 2001
    ..These findings suggest targeting of PDGF receptors as a novel treatment strategy for DFSP and GCF...
  9. ncbi Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
    K Pietras
    Ludwig Institute for Cancer Research, Uppsala, Sweden
    Cancer Res 61:2929-34. 2001
    ..The data suggest interference with PDGF receptors, or their ligands, as a novel strategy to increase drug uptake and therapeutic effectiveness of cancer chemotherapy...
  10. ncbi The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB
    A Shimizu
    Ludwig Institute for Cancer Research, Uppsala, Sweden
    Cancer Res 59:3719-23. 1999
    ..Our findings, thus, suggest that PDGF receptors could be a target for pharmacological treatment of DFSP and giant cell fibroblastoma, e.g., through the use of PDGF receptor kinase inhibitors such as CGP57148B...
  11. pmc Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease
    D Re
    Department of Internal Medicine I, University of Cologne, Joseph Stelzmann Strasse 9, 50931 Cologne, Germany
    Br J Cancer 86:1333-5. 2002
    ..Results suggest that patients with Hodgkin's disease may not benefit from therapy with STI571...